Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other Non-Current Liabilities (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $472000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities rose 5.59% year-over-year to $472000.0, compared with a TTM value of $472000.0 through Sep 2025, up 5.59%, and an annual FY2024 reading of $426000.0, up 19.33% over the prior year.
  • Other Non-Current Liabilities was $472000.0 for Q3 2025 at Autolus Therapeutics, down from $477000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $477000.0 in Q2 2025 and bottomed at $115000.0 in Q2 2022.
  • Average Other Non-Current Liabilities over 5 years is $310500.0, with a median of $383000.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities dropped 9.38% in 2022, then surged 240.16% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $128000.0 in 2021, then decreased by 9.38% to $116000.0 in 2022, then skyrocketed by 207.76% to $357000.0 in 2023, then increased by 19.33% to $426000.0 in 2024, then grew by 10.8% to $472000.0 in 2025.
  • Business Quant data shows Other Non-Current Liabilities for AUTL at $472000.0 in Q3 2025, $477000.0 in Q2 2025, and $444000.0 in Q1 2025.